Discontinue Antibiotics Now
Yes, discontinue the ertapenem-meropenem regimen immediately in this clinically stable patient with no signs of infection and normal laboratory tests. 1, 2
Evidence-Based Rationale
The most recent and authoritative guidelines support early antibiotic discontinuation in your exact scenario:
Primary Guideline Recommendations
For patients without documented infection:
- Discontinue empirical antibiotics when blood cultures are negative at 48-72 hours, the patient has been afebrile for ≥24 hours, and shows clinical stability 1
- The 2023 ECIL-4 guidelines (endorsed internationally) specifically recommend stopping antibiotics at 72 hours or later in clinically stable patients without proven infection who are afebrile for 48 hours, regardless of neutrophil count 2
Key Decision Points Supporting Discontinuation
Your patient meets ALL criteria for safe discontinuation:
- No clinical signs of infection (clinically stable)
- Normal laboratory parameters (no inflammatory markers suggesting occult infection)
- No documented pathogen (negative cultures)
- Afebrile (implied by "not sick")
What the Evidence Shows
The 2023 guideline review analyzed multiple studies comparing early cessation versus continuation until neutrophil recovery 2:
- No mortality difference between groups
- Some studies showed increased fever recurrence (3/7 studies) but this did NOT translate to worse outcomes
- Average of 2 antibiotic days saved
- Critical finding: One study actually showed MORE deaths in the continuation group, primarily from respiratory and fungal infections
Important Caveats and Monitoring
Continue antibiotics ONLY if:
- Pseudomonas aeruginosa bloodstream infection documented (requires longer courses) 2
- Patient becomes clinically unstable
- New fever develops
- Signs of infection emerge
FDA Warning to Consider
Prolonged carbapenem use increases risks of 3:
- C. difficile infection (can occur up to 2 months post-treatment)
- Drug-resistant organism development
- Seizure risk (especially with renal impairment)
- Drug interactions (particularly with valproic acid)
Post-Discontinuation Plan
Monitor closely for:
- Fever recurrence (occurs in minority but manageable)
- Clinical deterioration
- New infectious symptoms
If fever recurs: Re-culture and restart antibiotics based on clinical assessment 1
The Antimicrobial Stewardship Imperative
Recent data emphasizes that continuing antibiotics "in the absence of a proven or strongly suspected bacterial infection...increases the risk of drug-resistant bacteria" 3. A 2026 study demonstrated that cumulative cefepime/carbapenem exposure directly correlates with development of resistant organisms 4.
Bottom line: Continuing ertapenem-meropenem in your asymptomatic patient with normal labs provides no benefit and creates measurable harm through resistance development and adverse effects.